ResMed's Reasonable Valuation Lures New Bull -- Market Talk

Dow Jones

Mar 06, 2025

2309 GMT - ResMed gets a new bull at Citi, where analyst Mathieu Chevrier points to the breathing-tech maker's strong EPS growth, free cash-flow and balance sheet. Raising his recommendation on ResMed's Australia-listed stock to buy from neutral, Chevrier values the company at 24 times projected fiscal 2026 earnings, in line with its pre-Covid average. Its current valuation of 22 times fiscal 2026 earnings therefore looks reasonable, he writes in a note. He points out that ResMed has seen little impact from the roll-out of new weight-loss drugs, and sees risks associated with such treatments being continuously pushed back. Citi lifts its target price 7.3% to A$44.00. Shares are at A$36.92 ahead of the open. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

March 05, 2025 18:09 ET (23:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517787689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517787689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517787689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 07:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517787689","market":"fut","top_or_hot":-1,"title":"ResMed's Reasonable Valuation Lures New Bull -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2309 GMT - ResMed gets a new bull at Citi, where analyst Mathieu Chevrier points to the breathing-tech maker's strong EPS growth, free cash-flow and balance sheet. Raising his recommendation on ResMed's Australia-listed stock to buy from neutral, Chevrier values the company at 24 times projected fiscal 2026 earnings, in line with its pre-Covid average. Its current valuation of 22 times fiscal 2026 earnings therefore looks reasonable, he writes in a note. He points out that ResMed has seen little impact from the roll-out of new weight-loss drugs, and sees risks associated with such treatments being continuously pushed back. Citi lifts its target price 7.3% to A$44.00. Shares are at A$36.92 ahead of the open. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 05, 2025 18:09 ET (23:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed's Reasonable Valuation Lures New Bull -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed's Reasonable Valuation Lures New Bull -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-06 07:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2309 GMT - ResMed gets a new bull at Citi, where analyst Mathieu Chevrier points to the breathing-tech maker's strong EPS growth, free cash-flow and balance sheet. Raising his recommendation on ResMed's Australia-listed stock to buy from neutral, Chevrier values the company at 24 times projected fiscal 2026 earnings, in line with its pre-Covid average. Its current valuation of 22 times fiscal 2026 earnings therefore looks reasonable, he writes in a note. He points out that ResMed has seen little impact from the roll-out of new weight-loss drugs, and sees risks associated with such treatments being continuously pushed back. Citi lifts its target price 7.3% to A$44.00. Shares are at A$36.92 ahead of the open. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 05, 2025 18:09 ET (23:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2008162690.USD","symbol_name":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2517787689","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517787689","pubTimestamp":1741216140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2309 GMT - ResMed gets a new bull at Citi, where analyst Mathieu Chevrier points to the breathing-tech maker's strong EPS growth, free cash-flow and balance sheet. Raising his recommendation on ResMed's Australia-listed stock to buy from neutral, Chevrier values the company at 24 times projected fiscal 2026 earnings, in line with its pre-Covid average. Its current valuation of 22 times fiscal 2026 earnings therefore looks reasonable, he writes in a note. He points out that ResMed has seen little impact from the roll-out of new weight-loss drugs, and sees risks associated with such treatments being continuously pushed back. Citi lifts its target price 7.3% to A$44.00. Shares are at A$36.92 ahead of the open. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4504":"桥水持仓","BK7501":"新冠治疗股","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4588":"碎股","BK7007":"医疗保健设备","BK4567":"ESG概念","RMD":"瑞思迈","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","RMD.AU":"Resmed DRC","BK4082":"医疗保健设备"},"translate_title":"瑞思迈的合理估值吸引新的牛市——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":0.9,"RMD":1},"content_text":"2309 GMT - ResMed gets a new bull at Citi, where analyst Mathieu Chevrier points to the breathing-tech maker's strong EPS growth, free cash-flow and balance sheet. Raising his recommendation on ResMed's Australia-listed stock to buy from neutral, Chevrier values the company at 24 times projected fiscal 2026 earnings, in line with its pre-Covid average. Its current valuation of 22 times fiscal 2026 earnings therefore looks reasonable, he writes in a note. He points out that ResMed has seen little impact from the roll-out of new weight-loss drugs, and sees risks associated with such treatments being continuously pushed back. Citi lifts its target price 7.3% to A$44.00. Shares are at A$36.92 ahead of the open. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2025 18:09 ET (23:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}